Acquisition, Expansion, Diversification: Myriad Looks to Evolve Beyond Cancer Diagnostics

Myriad has acquired Rules-Based Medicine, taken steps to establish a European presence, and bolstered its companion diagnostics capabilities in an attempt to squelch negative Wall Street perceptions that it's a one-product company.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.